Aarti Drugs Limited Reports Audited Consolidated and Standalone Earnings Results for First Quarter Ended June 30, 2017
August 18, 2017 at 04:34 am EDT
Share
Aarti Drugs Limited reported audited consolidated and standalone earnings results for first quarter ended June 30, 2017. For the quarter, the company reported standalone total income of INR 2,483.2 million, profit before exceptional items and tax of INR 155.2 million, profit before tax of INR 155.2 million, profit for the period of INR 105.7 million or INR 4.43 basic and diluted share compared to the total income of INR 2,949.7 million, profit before exceptional items and tax of INR 251.4 million, profit before tax of INR 251.4 million, profit for the period of INR 173.4 million or INR 7.16 basic and diluted share, for the same quarter a year ago. Profit for the period from continuing operations was INR 105.7 million compared to INR 173.4 million for the same quarter a year ago.
For the quarter, on consolidated basis total income of INR 2,772.6 million, profit before exceptional items and tax of INR 167.2 million, profit before tax of INR 167.2 million, profit for the period of INR 113.8 million or INR 4.77 basic and diluted share compared to the total income of INR 3,158.0 million, profit before exceptional items and tax of INR 284.9 million, profit before tax of INR 284.9 million, profit for the period of INR 198.8 million or INR 8.21 basic and diluted share, for the same quarter a year ago. Profit for the period from continuing operations was INR 113.8 million compared to INR 198.8 million for the same quarter a year ago.
Aarti Drugs Limited is an India-based company that is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.